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It is increasingly accepted that sunscreens should protect against ultraviolet radiation (UVR)-induced immuno-
suppression, with an index of protection that can be compared with the sun protection factor (SPF). Five groups of
immunoprotection researchers met to discuss the status of immune protection factor (IPF) evaluation in human
skin in vivo. Current methods rely on a suncreen’s inhibition of UVR-induced local suppression of the contact
hypersensitivity (CHS) response or the delayed-type hypersensitivity (DTH) response, using either the induction or
the elicitation arms of these responses. The induction arm of the CHS response has the advantage of being
sensitive to a single sub-erythemal exposure of solar-simulating radiation (SSR) that allows a direct comparison
with the SPF. This approach, which necessitates sensitization, requires a large number of volunteers and is too
labor intensive and time consuming to become a routine method. The elicitation arm of the CHS or DTH responses
exploits prior sensitization to contact or recall antigens and has the advantage of being possible to apply on small
groups of volunteers. Some current protocols, however, require repeat SSR exposures, which invalidates a direct
comparison with SPF that is based on a single exposure. There is a need for a new simpler method of IPF that will
have to be validated against existing models.
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Human ultraviolet radiation (UVR)-induced immunosuppres-
sion (Cooper et al, 1992; Kelly et al, 1998, 2000) probably
plays a role in skin cancer (Nishigori et al, 1996; de Gruijl,
2002; Ullrich, 2002). The standard method of assessing
sunscreen protection is based on erythema and is ex-
pressed as the sun protection factor (SPF). It is recognized
that labelled SPF is often not achieved, because users typ-
ically apply sunscreens at lower application densities than
the 2 mg per cm2 required by regulatory bodies (Diffey,
1996). Quite apart from the behavioral issues that determine
the actual SPF achieved from a product, erythema is a poor
indicator of immunosuppression (Kelly et al, 2000). This
raises the question: ‘‘Is the immune protection factor (IPF) of
a sunscreen equivalent to its SPF?’’ Several studies (e.g.,
Ullrich et al, 1999; Cooper et al, 2002) indicate that sun-
screens afford some protection against UVR-induced
immunosuppression, but wide variations in experimental de-
sign and data management make it difficult to standardize the
assessment and definition of IPF. An expert panel (Table I),
convened by L’Ore´al Recherche in Paris on 5th of July 2002,
discussed these issues, which form the basis of this paper.
Immunological Background to IPF
Methodology
UVR suppresses the induction and elicitation arms of the
contact hypersensitivity (CHS) and delayed-type hypersen-
sitivity (DTH) responses. CHS is a response to topically
applied antigens, whereas DTH is the reaction to intracu-
taneously delivered antigens. Exposing naı¨ve volunteers to
UVR before antigen sensitization assesses suppression of
the induction arm. This assessment is made by challenge
with the same antigen 2–3 wk later. The assessment of the
suppression of the elicitation arm is made on volunteers
with prior sensitization via vaccination or environmental ex-
posure to common contact allergens such as nickel. In this
case, the volunteers are exposed to UVR and re-challenged
with the relevant antigens or contact allergen. Failure to in-
duce or elicit sensitization by applying or delivering the
antigen to the UVR-exposed site is called local immuno-
suppression and failure to induce or elicit sensitization by
applying or delivering the antigen to a non-UVR exposed
distant site is called systemic or distal immunosuppression.
Abbreviations: CHS, contact hypersensitivity; DNCB, dinitrochloro-
benzene; DTH, delayed-type hypersensitivity; EI, erythema index;
ID50, UVR dose that results in 50% immunosuppression; IPF, im-
mune protection factor; MED, minimal erythemal dose; MISD,
minimal immunosuppressive dose; PAR, primary allergic response;
SFT, skin fold thickness; SPF, sun protection factor; SSR, solar-
simulated radiation; ts, total score; UVR, ultraviolet radiation
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The IPF of a sunscreen has been evaluated using the in-
duction or elicitation arm of the local CHS or DTH response
(see Table I), and the systemic DTH response (Moyal and
Fourtanier, 2001).
Methodology Used by the Five Groups
Sunscreens It is important to characterize the sunscreens
studied. Apart from their names and concentrations, actives
such as antioxidants should be noted as these may influ-
ence UVR-induced immunosuppression. Sunscreen absorp-
tion spectra should be determined spectrophotometrically
in vitro, using either a Transpore tape (3M, Reuil, Malmaison,
France) (Diffey and Robson, 1989) or a roughened quartz
plate (Moyal and Fourtanier, 2001) as a substrate. Such
spectral data enable the calculation of different in vitro fac-
tors such as SPF and critical wavelength (lc) (Diffey, 1994).
It is very important to verify the in vivo assigned SPF
because this depends on the solar-simulating radiation
(SSR) source used for its assessment (LeVee et al, 1980), as
well as the method of sunscreen application and the clinical
evaluation of erythema. In all cases, the same SSR source
and similar volunteers (phototype, age range, sex ratio, and
body site) as those included for IPF assessment should be
used. Furthermore, the same investigator should apply the
sunscreen for SPF and IPF assessments. The European
Cosmetic Toiletry and Perfumery Association (Colipa, 1994)
or the Food and Drug Administration (FDA, 1999) recom-
mendations should be followed for SPF determination.
Erythema intensity can be assessed clinically or quantified us-
ing colorimetric measurements (Chromameter Minolta, Osaker,
Japan; Diastron Dia-stron, Andover, Oklahoma) (Colipa, 1994).
UVR sources and dosimetry SSR spectrum must comply
with a standard for SPF determination (e.g., Colipa, 1994). It
is important to measure SSR spectral irradiance at skin level
with a calibrated spectroradiometer. Routine spectroradi-
ometry is time consuming so calibrated broadband radi-
ometers are usually used for day-to-day measurements.
Volunteers and test sites Inclusion criteria, such as sex,
skin type, and test site, may influence the results. Immunity
decreases with age but the effect of age on photoimmuno-
suppression is unknown. The volunteers in the studies of
Table I ranged from 18 to 71 y old (UK: 18–35, Austria: 18–
60, France 18–40, Australia 18–71, USA: 18–60). Menstru-
ating women undergo marked monthly fluctuations in their
immune responsiveness but at mid-cycle, their immune re-
sponse is similar to men (Oberhelman et al, 1992). The UK
and US groups sensitized females at mid-cycle to control
for this. The Austrian and French groups dropped females
from the sunscreen IPF testing because of variability in re-
sponse observed in the first part of their study. It is easier to
find females for nickel elicitation studies because more
women (15%) than men (5%) develop allergic dermatitis
to nickel. The UK group has shown that susceptibility to
immunosuppression (induction of CHS) is skin type de-
pendent (Kelly et al, 2000), with skin types I/II being more
readily suppressed than skin types III/IV. But the Australian
group found no relationship between susceptibility to sun-
burn, which is roughly skin type dependent, and suscep-
tibility to suppression of the elicitation of CHS to nickel
(Damian et al, 2001).
All groups, except the Australians, assessed individual
sensitivity to SSR by determination of the minimal erythemal
dose (MED) 48 h to 2 wk before the immune function assays.
The MED is the SSR dose (J per m2) required to induce a just
visibly perceptible erythema or an erythema with well-de-
fined borders 24 h after exposure. The buttock was the sen-
sitization site for induction of CHS studies because this area
is relatively flat with an even color and, in general, UVR naı¨ve.
The buttock is not suitable, however, for DTH because of its
softness makes it difficult to give a homogeneous intracu-
taneous delivery of allergens. In this case, the back is pre-
ferred, which was also used for the elicitation of CHS to
nickel because it offers a larger flat area than buttock skin.
For induction studies, the challenge (or elicitation) was al-
ways performed on the UVR-protected upper inner arm, op-
posite to the UVR-exposed site (left arm when right buttock).
It is important that both SPF and IPF determinations are
based on a set of homogeneous volunteers with the same
inclusion criteria. Moreover, for IPF determination in elicitation
studies, the initial immune response of the volunteers has to
be considered for randomization of different groups, and for
selection of nickel concentrations used in the challenge
patches. It is important to note that comparisons between
IPF and SPF must be made in the same anatomical sites.
SSR doses and group design In general, the group size
was 6–15 volunteers. All groups except one (Australian)
based SSR doses on individual MED, giving fractions or
multiples of the individual MED that were determined prior
to the immunological protocols. Single SSR exposure
protocols used doses between 0.25 and 3 individualized
MED on unprotected sites. In repeated exposure protocols,
which assessed the suppression of nickel-induced CHS, all
volunteers received the same SSR doses that were not
greater than 1 mean MED per exposure. This limits the SSR-
induced erythema, which could otherwise interfere with the
assessment of CHS. The mean MED was determined on a
different but comparable group of volunteers.
The sunscreen-treated sites received MED increments
that were comparable with unprotected skin after the test
Table I. Investigative groups and techniques used to assess
immunoprotection
Group
Techniques used for IPF
assessment
Relevant
references
Australian Suppression of elicitation
response to nickel CHS
Poon et al (2003)
Austrian Suppression of sensitization
to DNCB
Wolf et al (2003)
French Suppression of elicitation
response to recall DTH
Moyal and Fourtanier
(2003)
UK Suppression of sensitization
to DNCB
Kelly et al (2003)
USA Suppression of sensitization
to DNCB
Baron et al (2003)
DNCB, dinitrochlorobenzene; IPF, immune protection factor; CHS,
contact hypersensitivity; DTH, delayed type hypersensitivity.
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product SPF had been taken into account, this being
0.253 MED  SPF. In general, the SPF was previously
determined on a separate group of comparable volunteers.
But, the US group determined the individual SPF, and the
SSR dose given to the sunscreen-treated individuals was
calculated using individual SPF.
With the exception of the Australian group, volunteers
were randomly assigned into either: SSRþ sunscreen or
SSR-only groups. In addition, control groups were included
such as no treatment at all, SSR exposed but non-sensi-
tized, non-SSR-exposed but sunscreen treated, and chal-
lenged only (for induction study). For the DTH elicitation
study, subjects allocated to the different groups were se-
lected based on their initial DTH responses. In the nickel
elicitation studies (Australian group), each volunteer re-
ceived a range of SSR doses with and without sunscreen as
well as control treatments (non-exposed-untreated, non-
exposed-sunscreen treated).
Immunological protocols to assess IPF
SSR suppression of the induction arm of the immune re-
sponse The Austrian, UK, and US groups used the CHS
response to a topically applied chemical hapten, din-
itrochlorobenzene (DNCB). Their protocols were very sim-
ilar, as shown in Fig 1. The hapten was dissolved at 31.2 mg
per 50 mL (0.0624%) either in ethanol (UK, Austria) or ac-
etone (US). The response to subsequent challenge was as-
sessed on five patches placed on the test site with
incremental doses of DNCB (generally from 3.125 to 25 mg
per 20 mL (0.015625%–0.125%) with a geometric progres-
sion) and a vehicle control.
Erythema on the buttock IPF test site, exposed with or
without sunscreen, was assessed clinically and/or by colo-
rimetry before sensitization with DNCB. The sensitization
was performed with a patch (in situ for 48 h) 24–48 h after
SSR exposure. The challenge on the inner arm, 2 or 3 wk
after sensitization, was with DNCB patches that were ap-
plied to each volunteer between 6 and 48 h. The elicitation
responses were measured 48–72 h after patch removal. The
primary allergic response (PAR) on the sensitization site was
always assessed, usually about 2 wk after the removal of
the initial DNCB patch. The severity of the PAR is an indi-
cator of the likely intensity of the elicitation response (Kelly
et al, 1998), and a strong PAR results in the exclusion of a
volunteer or a reduction of the DNCB challenge concentra-
tions to prevent severe blistering.
SSR suppression of the elicitation arm of immune respon-
se Two groups used the elicitation arm of the immune re-
sponse (See Fig 2). The French group used a commercial kit
(Multitest kit Pasteur Me´rieux, Lyon, France) that contained
seven antigens (tetanus toxoid, diphteria toxoid, Strepto-
coccus, tuberculin, Candida albicans, Trichophyton men-
tagrophytes, and Proteus mirabilis) encountered in child-
hood immunization and their vehicle (70% sterile glycerine).
These antigens are delivered intracutaneously, so they induce
DTH reactions. The Australian group used nickel (nickel sul-
fate), which is a common contact allergen, that was topically
applied in a petrolateum base to elicit the CHS response.
The French group assessed DTH responses 48 h after
challenge. Baseline immunity 1 wk prior to SSR exposure
was determined in each volunteer. The volunteers were then
exposed to SSR (based on MED previously assessed) and
were re-challenged 24 h later. In addition, the erythemal
response on the exposed sites, with or without sunscreen,
was evaluated by clinical scoring or/and colorimetry before
challenge. The Australian group enrolled nickel-sensitive
volunteers and measured the CHS response 24 h after the
removal of nickel patches that were left in situ for 48 h. In
this study, each volunteer was exposed to the same SSR
dose for 4 consecutive days. Two lots of nickel patches
were applied on each volunteer. The first lot was on the first
day of irradiation at a site distant from the test area. This
was to assess the initial CHS response and select the nickel
concentration for IPF assessment. The second lot of patch-
es was applied on the final day of SSR exposure. Erythema
induced by repeated sub-erythemal exposure (with or with-
out sunscreen) was assessed at the same time as the nickel
response, 72 h after the last SSR exposure.
Figure1
Study protocols used by Austrian, UK and USA groups for eval-
uation of solar-simulating radiation (SSR) suppression of the in-
duction arm of contact hypersensitivity (CHS) response.
Figure2
Study protocols used by Australian and French groups for evalu-
ation of solar-simulating radiation (SSR) suppression of elicitation
arm of the contact hypersensitivity (CHS) or delayed type hyper-
sensitivity (DTH) response.
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Quantiﬁcation of responses
Suppression of induction Subjective (clinical score) and
quantitative methods were used to assess the CHS re-
sponse and the results were expressed in different ways.
The UK group determined the percentage increase in der-
mal thickness by 20 MHz ultrasound image analysis and
scans were performed immediately before, and 48 and 72 h
after the challenge. The slope of linear regression analysis of
these measures represented the CHS response of a given
volunteer, in other words, the slope of the DNCB dose–
response. The Austrian group also took ultrasound meas-
urement but in addition measured the reaction diameter.
They used the average CHS response of all elicitation sites
for a given volunteer, as they had previously observed a
linear relationship between CHS response and DNCB con-
centrations. The US group determined the increase in skin-
fold thickness (SFT) at each elicitation site, and an overall
score per volunteer was given by the sum of the SFT of all
elicitation sites. Each challenge site was measured before
and after patch application. In addition, the three groups
visually scored the CHS responses. The US group used the
North American Contact Dermatitis Group system (Baron
et al, 2003). The Austrian (Wolf et al, 2003) and the UK (Kelly
et al, 1998) groups used their own defined grading systems.
Suppression of elicitation The French group summed the
mean diameter of each positive reaction to each recall an-
tigen to obtain a total score (TS) for each volunteer. Reac-
tion borders were defined by redness and induration. The
Australian group quantified the CHS response to nickel by
determining an erythema index (EI) by reflectance spec-
troscopy. After subtraction of the background (absence of
nickel patch), the EI of the exposed sites (with or without
sunscreen) were compared with the EI of the appropriate
unirradiated nickel-patched sites. The results are expressed
as DEI¼EI (unirradiated control)EI (test site).
IPF calculation
Suppression of induction studies The IPF was derived from
the CHS responses of all sensitized volunteers. IPF was
either considered as the ratio, between unprotected and
protected groups, of a particular endpoint such as the SSR
dose that induced 50% immunosuppression (ID50), or as the
ratio of the two SSR dose–responses-modelled curves for
CHS responses with and without sunscreen. In both ap-
proaches, the dose–response relationship between individ-
ual CHS response and the dose of SSR given were
modelled for both unprotected and protected groups with
the same nonlinear regression models. Generally, two-pa-
rameter exponential (1) or logistic curves (2) were fitted,
based on the following types of equations:
y ¼ c  exp b dose
IPF
 
ð1Þ
where y is the immune response, IPF equals 1 for unpro-
tected groups, b40, and c is the maximal immune response
y ¼ c f ðdose  b=IPFÞ
a
 
ð2Þ
where y is the immune response, f(x)¼ ex/(exþ1), b is ID50
for unprotected groups, IPF equals 1 for unprotected
groups, ao0, and c is the maximal immune response. It is
assumed that at high doses, there is complete suppression
of immune reaction. For this model, the logarithm of dose
instead of dose might be used, making the dose curve flat-
ter at high doses and steeper at low doses.
Improved curve modelling (generally because of the non-
normality of the distribution of the residuals) was sometimes
achieved by transforming the CHS responses before fitting
(e.g., square root or log transformation). The relationship
between the variance of the CHS measurements and the
SSR dose was included in the fitting of the logistic model.
Estimates for IPF with their 95% bilateral confidence inter-
vals were calculated directly from the data, and were some-
times improved by bootstrapping.
Suppression of elicitation studies The French group carried
out a limited dose–response study (three SSR doses) with
the Multitest kit that did not provide sufficient data for an
exact IPF determination. It has not been possible to expand
the study because the kit is out of production. But, it was
possible to determine whether the IPF was equal or not to
the SPF by comparing each pre- and post-SSR DTH score
with a paired t-test. Then, comparisons between sunscreen
and non-sunscreen groups were performed on the variation
of TSs (pre-SSRpost-SSR) by analysis of variance and
Tukey’s tests.
The Australian group compared the EI induced by the
nickel CHS response (minus the skin background color) at
non-SSR exposed sites with the EI at test sites. Statistical
significance was assessed by the paired t-test to determine
the amount of SSR to achieve immunosuppression. The
SSR doses that reduced the mean EI of unirradiated skin by
20% were calculated, for both protected and unprotected
sites, and were defined as minimal immunosuppressive
doses (MISD). The IPF was calculated from the ratio of
MISD of protected and unprotected skin using pooled rath-
er than individual volunteer data.
Pros and cons of each method
Suppression of induction studies
Advantages Local suppression of the induction of
CHS occurs at sub-erythemal doses and
at doses lower than those needed for
suppression of elicitation. It is therefore a
very sensitive endpoint, especially for
skin types I and II. Its great advantage
for sunscreen IPF evaluation is that the
duration of SSR exposure is less than
those of other methods that require high-
er or repeated SSR doses.
Disadvantages This method requires active sensitization
of the volunteers. However the allergen
(DNCB) is not in any commercial prod-
ucts, so volunteers are unlikely to en-
counter it again. However if this occurs,
the dermatitis is localized and can be
easily treated with mild topical steroids.
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As it is not possible to test different dos-
es of SSR with and without sunscreen on
a single subject, many volunteers are
needed so the whole procedure is ex-
pensive. This technique takes 3 weeks
but in practice the method takes much
longer because it is not possible to han-
dle the large number of volunteers need-
ed simultaneously.
Suppression of elicitation responses
Multitest Kit Merieux
Advantages As with all studies on the elicitation re-
sponse, this method does not require the
sensitization of the volunteers but it is
important to verify the initial level of im-
munity that is very variable. Most people
have been immunized in childhood so
enrolment of volunteers is easy. The test
kit, with a battery of seven antigens, pro-
vides comprehensive information on the
immune status of the volunteers. Finally,
the entire protocol can be completed
within 2 weeks.
Disadvantages The Multitest is about 50 cm2 so it re-
quires a large SSR exposure area. An
acute exposure significantly depress the
DTH response but requires doses more
than 1 MED. Under these conditions a
systemic effect has been observed. This
means that SSR dose–response studies
with and without sunscreen require dif-
ferent groups of volunteers with each
volunteer receiving only one SRR dose
with or without the sunscreen. The main
disadvantage is that this kit is out of pro-
duction. However the Mantoux testing
with tuberculin purified protein derivative
provides a possible alternative model of
DTH to a recall antigen.
CHS to nickel
Advantages This protocol takes advantage of volun-
teers who have already been sensitized,
but a sex bias can be introduced as more
women than men are allergic to nickel.
The size of the SSR exposed site can
be small as the nickel patch diameter is
only 9 mm (Finn Chambers). This method
enables the determination of SSR-induced
immunosuppression dose–responses with
and without sunscreen on a single group
of volunteers because no systemic effect
has been observed with the protocols
used. The entire protocol takes 1 week.
Disadvantages The protocol requires several SSR expo-
sures. Although a recent unpublished
study found similar results with a single
SSR exposure (T. S. Poon et al, personal
communication). An acute higher SSR
dose may suppress the response but its
resulting erythema may mask the nickel-
induced erythema CHS reaction. Repeat
exposures make it difficult to compare
protection afforded by a sunscreen
against immunosuppression with SPF
that is based on a single exposure. Cur-
rent protocols have not used individual-
ized MED data but this could be readily
done if thought appropriate. At a low
concentration of nickel, adapted to the
individual sensitivity of the volunteer, the
reactions are mild and can be difficult to
measure. The pooling of data is required
to overcome inter-individual variation.
Discussion Questions and Answers
Which model is more relevant for the prediction of ef-
ﬁcacy of sunscreen protection against the development
of skin cancer? Animal and human studies that link pho-
tocarcinogenesis to UVR-induced immunosuppression are
based on the suppression of the induction arm of cell-me-
diated immunity. The role of suppression of the induction
arm is not known. But, as carcinogenesis is a long process
with new tumor antigens arising during progression, and
tumor antigen concentration increases as tumors develop, it
is likely that neither CHS nor DTH accurately mimics antigen
exposure during development of anti-tumor immunity.
Which is the best immunological endpoint for IPF as-
sessment: Suppression of induction or elicitation arms
of the responses? A definitive answer is not possible at
present. Different mechanisms are probably involved in
these immune responses, although this has received insuf-
ficient research attention. Both methods are suitable from a
technical point of view.
Which method will be the best to evaluate CHS re-
sponse? Different clinical and quantitative methods, such
as diameter, area, color, edema, ultrasound, and SFT, can
be used; some of which were found to give similar results by
the Austrian and US groups. Routine testing is best con-
ducted with simplified protocols that may include one
quantitative method in addition to a clinical score.
Must comparisons of IPF and SPF be made with the
same methods, volunteers, SSR sources and body
sites? Comparisons of IPF and SPF must be made with
similar protocols. When IPF is determined from dose–re-
sponse analyses on different groups of volunteers, protec-
tion against erythema should also be quantified in parallel,
based on the entire SSR dose–response. The erythema
protection factor obtained cannot be called an ‘‘SPF,’’ as
this term has been defined by regulatory bodies (FDA and
Colipa). The name Ery-PF has been proposed by the UK
group (Fourtanier et al, 2000; Kelly et al, 2003), which found
this value was comparable with the SPF.
Should SSR doses, in IPF determination, be fractions or
multiples of individual MED or physical doses (J per
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cm2) without taking into account individual SSR sensi-
tivity? The SSR dose range must be defined by taking into
account the volunteers’ skin type and MED from experi-
mental, published, or historical data. The dose given to
sunscreen-treated groups should be that given to the un-
treated volunteers (MED or J per cm2) multiplied by the SPF.
The SPF may be the mean SPF determined in a different
group of comparable volunteers, or the individual SPF
measured on each volunteer included in the experimental
groups as was carried out by the US group. This approach,
however, requires considerably more work.
None of the groups had any experience with a design
based on arbitrary SSR doses (e.g., within a tolerable
range with arithmetic or geometric progression), making it
difficult to evaluate this type of protocol. The statisticians,
however, thought that this approach would be more valu-
able and easier.
The choice of SSR dose in the nickel CHS studies should
be based on the considerations given above, bearing in
mind that four repeated exposures were used to suppress
the response. Thus, the highest daily SSR must not be
greater than 1 MED or 1 MED  SPF on protected sites.
Doses greater than 1 MED are required for the recall antigen
DHT studies, which limits the dose range because it is un-
ethical to give doses more than 3 MED or 3 MED  SPF.
Furthermore, edema induced by high SSR doses may com-
promise the DTH reading.
Is it essential to determine an exact IPF because this
index will have limited value for the consumer, and will
the regulatory authorities recognize it? The current as-
sessment of IPF with a single SSR exposure is based on the
suppression of the induction of CHS. This requires SSR
dose–response studies, with and without sunscreen, from
which IPF is derived from a global ratio (i.e., over the entire
dose–response range) that is different from the threshold
approach to SPF assessment. The UK group tested differ-
ent global models and found similar estimations for IPF, re-
sulting in the conclusion that it is best to use the simplest
model that defined the general shape of the generally
exponential curves.
As untreated and sunscreen-treated responses can be
obtained on a single volunteer in the nickel CHS studies, it
may be preferable to use a threshold method similar to that
for SPF. The MISD, which is the minimum significant effect
that is significantly detectable from pooled data, has been
proposed, and the IPF is the ratio of MISD protected/MISD
unprotected.
A proposed improvement of the IPF calculation would be
to use a global two-stage method (Steimer et al, 1984),
which consists of first estimating each individual IPF from
each individual antigen dose–response curve and then es-
timating an IPF from all individual IPF, taking into account
the individual variability’s weighted average.
At present, there is no need to label sunscreens with an
exact IPF index. In part, this is because consumers still have
problems understanding the SPF number, which has been
capped at 30 in some countries (Australia, USA) resulting in,
possibly confusing, labels such as ‘‘SPF 30 plus.’’ Further-
more, there is an increasing trend for indices of UVA pro-
tection with which the consumer is still not fully familiar.
Labelling the product with an additional protection index,
e.g., IPF, may add to consumer confusion, especially when
it is not easy to specify what the exact benefits might be.
Growing concerns about the possible adverse effects of
solar UVR on immunity, however, may prompt health and
cosmetic authorities to require industry to include evidence
of immunoprotection, which is as least equivalent to SPF, in
application files for new sunscreen products. A pass or fail
option, as discussed in following section, could satisfy such
a requirement, and would also be faster and much less ex-
pensive for the sunscreen industry to adopt.
Even if exact IPF determination is not crucial, the panel
thought that the level of protection against immuno-
suppression should be at least equal to that for ery-
thema. What protocol is best for this assessment? A
simplified protocol should be validated against existing
methods. In this context, it is worth noting that SPF as-
sessment using a single exposure on sun-protected skin
has been proposed by Diffey (2003).
Suppression of induction of CHS Volunteers would be se-
lected on the basis of their SSR MED (J per cm2) within a
narrow range (e.g., 4  0.4 J per cm2). This range encom-
passes skin type I, II, and III as previous work showed
considerable overlap of SSR MED within different skin types
(Harrison and Young, 2002), and so it would be better to
select volunteers within defined skin types. After selection,
volunteers would be randomly assigned to three different
groups receiving either (i) no topical treatment and no SSR
exposure, (ii) no topical treatment and d J per cm2 of SSR,
where this dose is sub-erythemal and sub-immunosup-
pressive in the study population, or (iii) sunscreen-treated
group with d J per cm2 multiplied by the mean SPF, meas-
ured on a separate group of volunteers or on these volun-
teers themselves with the same SSR source. The definition
of sub-immunosuppressive would have to be clearly de-
fined and could for example be about 50% suppression of
control after determination from dose–response studies un-
der the same conditions. An additional control group could
be considered, (iv) sunscreen treatment but no SSR, to as-
sess the effect of topical treatment on sensitization. If the
IPF¼SPF or IPF4SPF, the group receiving d  SPF J per
cm2 will be protected for both endpoints, showing no ery-
thema or immunosuppression. If IPFoSPF, the d  SPF
J per cm2 group will show no erythema but may show
immunosuppression.
Data analysis should include a non-inferiority test be-
tween non-sunscreen treated and SSR and sunscreen and
SSR groups, the objective being to prove that the response
in the treated group is at least the same as that in the non-
treated group exposed. In addition, it would also be desir-
able to perform a comparison test between both nontreated
groups, with and without SSR, to verify whether d per cm2
induces a significant immunosuppression. Some simula-
tions showed that a fair power is accessible but a specific
experiment is certainly needed for a correct assessment.
Groups of 15 volunteers may be sufficient.
A statistical analysis of all data has shown similar IPF
when calculations were based on one DNCB concentration,
e.g., 12.5 mg per 20 mL. The lower concentrations (0, 3.125,
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6.25 mg per 20 mL) gave unreliable data with a high inter-
individual variation. The high concentration (25 mg per 20 mL)
sometimes induces very severe reactions and is unusable
for some subjects.
Thus, it would be better to apply four patches using the
same DNCB concentration (e.g., 12.5 mg per 20 mL plus one
patch soaked in the vehicle), which would reduce the var-
iability of response. Variability can also be reduced by the
use of a quantitative method to measure CHS response
after taking the pre-challenge value into account.
Suppression of the elicitation of CHS to nickel A desirable
improvement of this technique would be to develop an assay
for the nickel CHS reaction that is different from skin redness
so that higher single SSR doses could be given. Skin edema
by ultrasound is a possible option. If the acute SSR dose
required to suppress the response is higher than 2 MED,
however, it will be difficult to use this protocol to determine
whether SPF¼ IPF as the exposure times with sunscreen
will be long and may induce edema in addition to erythema.
The daily doses to unprotected sites have to be lower than 1
MED if repeated SSR doses are essential for suppression.
Kuchel et al (2002) reported that 4 daily 0.5 MED exposures
induced suppression without any confounding erythema,
when the CHS assessment was made 72 h after the last
SSR exposure. A protocol similar to that described for the
suppression of induction would be possible.
Conclusion
More research into the relationship between the modulation
of the skin’s immunity by solar UVR and human skin cancer
is required. In the absence of this knowledge, it is prudent to
propose that sunscreen use should not substantially alter
the relationship between UVR-induced erythema and im-
mune modulation. This can only be achieved if the SPF and
IPF of a sunscreen are comparable, and this relationship
should be maintained even when the sunscreen is applied
such that it will not achieve the labelled SPF, as is often the
case in practice. It is recognized that the basis of current
endpoints for IPF assessment is pragmatic and within this
context there is a need for a standard method of IPF de-
termination that is simple and robust.
DOI: 10.1111/j.0022-202X.2005.23857.x
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